Wells Fargo & Company Issues Positive Forecast for aTyr Pharma (NASDAQ:ATYR) Stock Price

aTyr Pharma (NASDAQ:ATYR) had its price objective hoisted by Wells Fargo & Company from $1.00 to $4.00 in a report released on Friday morning,Benzinga reports. The brokerage currently has an equal weight rating on the stock.

A number of other brokerages have also recently issued reports on ATYR. Weiss Ratings cut shares of aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 16th. Wall Street Zen upgraded aTyr Pharma to a “hold” rating in a research report on Saturday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, aTyr Pharma presently has an average rating of “Hold” and a consensus target price of $5.00.

aTyr Pharma Price Performance

Shares of ATYR traded up $0.32 during trading hours on Friday, hitting $6.35. The company’s stock had a trading volume of 66,192 shares, compared to its average volume of 83,642. The company has a market cap of $15.56 million, a price-to-earnings ratio of -0.29 and a beta of 1.04. The business has a 50 day simple moving average of $11.68 and a two-hundred day simple moving average of $23.59. aTyr Pharma has a 52-week low of $4.07 and a 52-week high of $44.40.

aTyr Pharma (NASDAQ:ATYR) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($7.43) EPS for the quarter, missing analysts’ consensus estimates of ($4.00) by ($3.43). The company had revenue of $235.23 million for the quarter, compared to the consensus estimate of $2.50 million. Research analysts predict that aTyr Pharma will post -17.80 earnings per share for the current year.

Institutional Trading of aTyr Pharma

An institutional investor recently bought a new stake in aTyr Pharma stock. Renaissance Technologies LLC purchased a new stake in aTyr Pharma, Inc. (NASDAQ:ATYR) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 40,522 shares of the company’s stock, valued at approximately $32,000. 61.72% of the stock is owned by institutional investors and hedge funds.

About aTyr Pharma

aTyr Pharma, Inc (NASDAQ:ATYR) is a biotechnology company focused on developing therapies that modulate immune system activity. The company’s research is based on a class of naturally occurring proteins known as extracellular tRNA synthetases, which can influence biological processes involved in inflammation, tissue repair and immune regulation.

aTyr’s lead product candidate is efzofitimod, an engineered protein therapeutic designed to target neuropilin-2 and regulate immune responses in the lungs.